Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urinary Bladder Neoplasms 8 Carcinoma, Merkel Cell 6 Neoplasm Metastasis 5 Carcinoma, Transitional Cell 5 Breast Neoplasms 5 Carcinoma, Renal Cell 4 Triple Negative Breast Neoplasms 2 Skin Neoplasms 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Neuroendocrine Tumors 2 Melanoma 2 Carcinoma, Non-Small-Cell Lung 2 Uveal Melanoma 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Thymoma 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Primary Myelofibrosis 1 Penile Squamous Cell Carcinoma (PSCC) 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplasms 1 Neoplasm, Residual 1 Muscle Invasive Bladder Urothelial Carcinoma 1 Metastatic Urothelial Cancer 1 Mesothelioma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1

Interventions

pembrolizumab 27 Cisplatin 18 Cetuximab 12 Carboplatin 12 Surveys and Questionnaires 8 Radiotherapy 8 Paclitaxel 8 Docetaxel 6 Radiotherapy, Intensity-Modulated 5 Surgical Procedures, Operative 4 dostarlimab 3 Therapeutics 3 Standard of Care 3 Fluorouracil 3 Cyclophosphamide 3 Chemoradiotherapy 3 Blood Specimen Collection 3 Albumin-Bound Paclitaxel 3 130-nm albumin-bound paclitaxel 3 toripalimab 2 nimotuzumab 2 fludarabine 2 durvalumab 2 atezolizumab 2 abemaciclib 2 X-Rays 2 Taxes 2 Radiosurgery 2 Radiation 2 Nivolumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Head and Neck Neoplasms × avelumab × 90 days × Clear all

NCT03494322 2026-05-20

EACH

University College, London

Phase 2 Completed

Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡